Jim Mazzola
Investor Relations Contact chez OUTSET MEDICAL, INC.
Postes actifs de Jim Mazzola
Sociétés | Poste | Début | Fin |
---|---|---|---|
OUTSET MEDICAL, INC. | Investor Relations Contact | 01/01/2022 | - |
Historique de carrière de Jim Mazzola
Anciens postes connus de Jim Mazzola
Sociétés | Poste | Début | Fin |
---|---|---|---|
CAREFUSION CORPORATION | Investor Relations Contact | 01/09/2008 | 01/03/2015 |
Public Communications Contact | 01/09/2008 | 01/03/2015 | |
Sales & Marketing | 01/09/2008 | 01/03/2015 | |
CARDINAL HEALTH, INC. | Public Communications Contact | 01/09/2003 | 01/09/2008 |
CareFusion Foundation | President | - | - |
HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - | |
TURG POIN | Investor Relations Contact | - | - |
Formation de Jim Mazzola
University of Dayton | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 8 |
Opérationnelle
Investor Relations Contact | 4 |
Public Communications Contact | 3 |
Sales & Marketing | 1 |
Sectorielle
Health Technology | 4 |
Distribution Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
CARDINAL HEALTH, INC. | Distribution Services |
HALOZYME THERAPEUTICS, INC. | Health Technology |
OUTSET MEDICAL, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
CareFusion Corp.
CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
CareFusion Foundation |
- Bourse
- Insiders
- Jim Mazzola
- Expérience